For innovation companies, highly differentiated and technologically advanced biobetters offer the greatest potential to mitigate the risks associated with the introduction of biosimilars, as they can be approved before the patent expires and have blockbuster potential.
Related Articles Read More >

NVIDIA and UW’s protein design model produces 158 binders from 188 designs

OpenAI deploys nearly 2,000 GPT-Rosalind agents to generate biological research leads in 32 minutes

Why promising technologies stall on the path to market: Lessons from medtech
